CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 8 enrolled
Drug / intervention
Ga-68 Galmydardrug
Likely dose
Single intravenous injection of 68Ga-Galmydar (specific activity dose not stated)AI-extracted
Key inclusion· 1
  • ✓Healthy men and women aged 18-99 years, any race
Key exclusion· 5
  • ✕Positive urine drug screen at screening or before dosing, or OTC/herbal drug use within 2 weeks before enrollment
  • ✕Concurrent or recent participation in another study with a study drug (diagnostic or therapeutic radiopharmaceutical) administered within 10 half-lives
  • ✕Severe claustrophobia
  • ✕Pregnant or breastfeeding

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05280782
NCT05280782Early Ph 1Completed
CompareCT.gov

Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging

Washington University School of Medicine·interventional·Posted Mar 15, 2022·Updated Sep 8, 2023

In Brief

A Early Phase 1 clinical trial evaluating Ga-68 Galmydar for Coronary Artery Disease. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This study is a single center, early phase 1 clinical imaging study designed to assess the dosimetry of 68Ga-Galmydar for PET/CT imaging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Early Ph 1CompletedFinished
20222023202420252026
First PostedMar 15, 2022
Enrollment StartJan 5, 2022
Primary CompletionMay 1, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.3 years ago

Interventions

Ga-68 Galmydardrug

Single intravenous injection of the PET radiotracer 68Ga-Galmydar.